The showdown of "weight loss miracle drugs": Lilly's Zepbound beats Novo Nordisk's Wegovy

On December 4th, Jinshi Data reported that Eli Lilly and Company stated that, in the first comparative trial of two blockbuster weight-loss drugs, the performance of the company's weight-loss drug Zepbound outperformed Wegovy (Victoza) from Novo Nordisk. In a study sponsored by Eli Lilly, subjects taking Zepbound lost an average of 20% of their weight - about 50 pounds - over 72 weeks, while those taking Wegovy lost 14%. This result confirmed previous trials of these two drugs, which showed that Zepbound had a stronger effect. The side effects of the two drugs are mainly related to the gastrointestinal tract and are similar. Lilly stated that the complete study results will be published in a peer-reviewed journal and will be presented at medical conferences next year. In Copenhagen, Novo Nordisk's stock price fell by 1.8%, and it has pumped about 11% this year. Lilly's (LLY.N) stock price pumped 2% before the opening of the US stock market.